SCENESSE® dosage expansion under review by European Medicines Agency 2024 Announcements . Clinical . News . Regulatory 20.11.2024
CLINUVEL prioritises three strategic programs 2024 Announcements . Clinical . News . Regulatory 18.11.2024
Appendix 3Z – Final Director’s Interest Notice 2024 Announcements . Financial . News . Regulatory 17.10.2024
CLINUVEL files Canadian New Drug Submission for SCENESSE® in EPP 2024 Announcements . Clinical . News . Regulatory 01.10.2024
SCENESSE® data to be presented at global porphyria conference 2024 Announcements . Clinical . News . Regulatory 20.09.2024
Initial Director’s Interest Notice — Dr Pearl Grimes 2024 Announcements . Financial . News . Regulatory 10.09.2024